This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Board meeting rescheduled to 4 November 2026
SHUKRAPHAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts more than Nifty Microcap 250 and 2.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board meeting was moved from 3 November to 4 November 2026. Directors will consider and approve unaudited financial results for the quarter and half-year ended 30 September 2026, together with the auditor's limited review report. No financial figures were provided.
The notice only changes the meeting date and gives no financial results. Shareholders must wait for the approved figures.
The company's XBRL figures for this quarter look filed in the wrong unit: revenue reads ₹44.20 Cr against ₹5.88 Cr a year ago, about 8× larger. A move that size is almost always a wrong unit, not a business, so nothing is computed from these figures and no number-based tags are set; the read above is the AI's, from the document.